NCT05968417|RecruitingDMC
Myeloma Novel Drug Discovery Ver 1.2
DISCO
Investigation of the Activity of Novel Compounds for the Treatment of Myeloma and Mechanisms of Drug Resistance to Current Therapies
Loading search results
Sponsor study identifier
observational
250
1 country
1
Study Start
July 22, 2020
Actual (reported)Primary Completion
February 28, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 28, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 28, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 22, 2020
Actual (reported)July 21, 2023
Actual (reported)August 1, 2023
Actual (reported)February 28, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
February 28, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Cell viability
Myeloma cell viability when incubated with standard of care and novel compounds.
12 months
Participants who are undergoing peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment will be approached to collect additional samples for research.
No intervention - blood and/or bone marrow sample collection only
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
The Royal Marsden NHS Foundation Trust
Sutton, SM25PT, United Kingdom
First Submitted
July 21, 2023
First Posted
August 1, 2023
Study Start
July 22, 2020
Actual (reported)Primary Completion
February 28, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
A New Study Evaluating the Activity of Modular CAR T for mYeloma
Contact the study team to confirm eligibility.
Study Completion
February 28, 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 3, 2023
Record last verified: 2023-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: